INVESTORS Annual Reports Financials Investor Presentations Shareholder Information Analysts Speak Events
LUPIN FOUNDATION
CAREERS Careers Overview Life at Lupin Campus Connect Learning & Development Current Openings P.L.E.D.G.E.
MEDIA Press Releases Lupin in News Downloadables
CONTACT US Contact Us Global Offices Partner With Us
 
2019 ▼
2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002

Lupin receives FDA approval for Levothyroxine Sodium Tablets USP

January 21, 2019

LupinLife’s Corcal Bone & Beauty to launch at Lakme Fashion Week with an initiative to bring #Beautifullystrong real women to the ramp

January 18, 2019

Orphan Drug NaMuscla® Receives European Commission Approval for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders

January 8, 2019

Lupin Pharmaceuticals, Inc. Issues Voluntary Recall of Ceftriaxone for Injection USP, 250mg, 500mg, 1g and 2g

January 7, 2019

Lupin receives FDA approval for Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg & 120 mg

January 7, 2019

Lupin receives FDA approval for Clobazam Oral Suspension, 2.5 mg/mL

December 31, 2018

Lupin and AbbVie Announce Partnership to Develop and Commercialize Novel Oncology Drug to treat Hematological Cancers

December 24, 2018

Lupin receives US FDA approval for Clobazam Tablets, 10 mg and 20 mg

December 17, 2018

Lupin receives tentative US FDA approval for Tadalafil Tablets USP, 20 mg

December 17, 2018

Lupin receives tentative US FDA approval for Dimethyl Fumarate Delayed Release Capsules, 120 mg and 240 mgn

December 13, 2018

Lupin’s Pithampur Unit-3 (Indore) receives EIR from US FDAon

December 10, 2018

US FDA completes inspection of Lupin’s Mandideep location

December 5, 2018

Lupin launches generic Silodosin Capsules 4mg and 8mg

December 4, 2018

Lupin launches generic Nystatin and Triamcinolone Acetonide Cream USP 100,000 units/gm; 0.1%

November 30, 2018

Lupin's Tarapur facility receives EIR from US FDA

November 27, 2018

Lupin receives FDA approval for Clomipramine HCl Capsules

November 26, 2018

Lupin receives FDA approval for KCl for Oral Solution 20 mEq

November 26, 2018

Lupin launches India's first chatbot for patients

November 23, 2018

Lupin launches generic Tetrabenazine Tablets

November 21, 2018

Lupin receives FDA approval for Decitabine for Injection, 50 mg/vial, Single-Dose Vial

November 15, 2018

Lupin receives FDA approval for Budesonide Inhalation Suspension, 0.5 mg/2 mL

November 13, 2018

Lupin launches generic Atovaquone Oral Suspension USP in the US

November 12, 2018

Lupin's Nagpur facility receives EIR from US FDA

November 9, 2018

Lupin receives FDA approval for Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials

November 5, 2018

Lupin Quarter II, FY2019 - Results

October 31, 2018

Lupin receives FDA approval for generic Triamcinolone Acetonide Ointment USP, 0.1%

October 22, 2018

Lupin Neurosciences Announces Positive CHMP Opinion for NaMuscla™ for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders

October 19, 2018

Lupin's Pithampur Unit-3 (Indore) Inspected by US FDA

October 19, 2018

Intimation to the Exchanges on Investors Call.

October 16, 2018

Survey Data Reveals the Need for Improved Communication Between Patients and Healthcare Providers About Bacterial Vaginosis (BV), the Most Common Gynecologic Infection in the U.S.

October 16, 2018

Notice to the Exchanges on Board Meeting

October 16, 2018

Lupin receives tentative FDA approval for generic Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg

October 15, 2018

Lupin launches generic Clobetasol Propionate Ointment USP 0.05% in the US

October 9, 2018

Lupin launches generic Potassium Chloride Oral Solution USP, 20 mEq/15mL (10%) and 40 mEq/15 mL (20%)

October 4, 2018

Lupin appoints Alok Sonig as CEO – US Generics and Global Head – Generics R&D & Biosimilars

September 18, 2018

Lupin appoints Dr. Kamal K. Sharma as Advisor to the Company

September 17, 2018

Lupin’s Nagpur facility inspection by US FDA concluded with no observation

September 14, 2018

Lupin receives FDA approval for generic Atovaquone Oral Solution USP

September 12, 2018

Lupin’s Tarapur API Manufacturing Facility Inspected by US FDA

September 4, 2018

Lupin receives FDA approval for generic Potassium Chloride Oral Solution USP

August 30, 2018

Lupin receives FDA approval for generic Gabapentin Tablets USP, 600 mg and 800 mg

August 28, 2018

Lupin launches generic Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg

August 27, 2018

Lupin’s Nagpur facility receives Establishment Inspection Report (EIR) from US FDA

August 24, 2018

Lupin enters dermatology segment in Brazil with launch of Lupin High-End Skin Science

August 23, 2018

Lupin receives tentative FDA approval for generic Nudovra (Estradiol Valerate Tablets, 3 mg and 1 mg and Estradiol Valerate and Dienogest Tablets, 2 mg/2 mg and 2 mg/3 mg) Tablets

August 22, 2018

Lupin launches generic Clobetasol Propionate Cream USP 0.05% in the US

August 21, 2018

Lupin receives FDA approval for generic Hydrocortisone Butyrate Lotion, 0.1%

August 21, 2018

Quarter I, FY2019 - Results

August 08, 2018

Intimation to the Exchanges on Investors Call

August 02, 2018

Lupin's Mandideep facility gets approval from EDQM

July 30, 2018

Lupin launches generic Desoximetasone Topical Spray, 0.25% in the US

July 27, 2018

Notice to the Exchanges on Board Meeting.

July 24, 2018

Lupin receives tentative FDA approval for generic Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg, and 20 mg

July 19, 2018

Lupin's Goa facility gets approval from UK MHRA

July 16, 2018

Lupin receives FDA approval for generic Nitrofurantoin Capsules USP (Macrocrystals), 50 mg and 100 mg

July 12, 2018

Boehringer Ingelheim India and Lupin expand collaboration for co-marketing of two oral anti-diabetic drugs

July 11, 2018

Lupin appoints Yashwant Mahadik as President - Global HR

July 10, 2018

Lupin receives FDA approval for generic Hydroxychloroquine Sulfate Tablets USP, 200 mg

July 09, 2018

Lupin announces tie-up with European Association of Urology (EAU)

June 29, 2018

Lupin and MCGM Unite to launch Anti-TB Campaign in Mumbai

June 29, 2018

Lupin and Mylan Partner to Commercialize Enbrel® (Etanercept) Biosimilar

June 28, 2018

Lupin and Nichi-Iko announce strategic partnership for commercialization of biosimilar Etanercept in Japan

June 18, 2018

Lupin receives FDA approval for generic Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg

June 14, 2018

Lupin launches generic Tobramycin Inhalation Solution USP in the US

June 13, 2018

Lupin receives FDA approval for generic Nystatin and Triamcinolone Acetonide Cream USP, 100,000 units/gram and 1mg/gram

June 04, 2018

Lupin launches generic Methylergonovine Maleate Tabs USP in the US

June 04, 2018

Lupin appoints Nicholas Hart as President - Specialty for US Business

May 31, 2018

Lupin launches Solosec™ (secnidazole) 2g Oral Granules in the US

May 31, 2018

Lupin submits Marketing Authorization Application for Etanercept Biosimilar in Europe

May 25, 2018

Lupin announces fiscal year 2018 Results, Board recommends dividend of 250%

May 15, 2018

Lupin's Nagpur facility US FDA inspection concluded with no observations

May 14, 2018

Lupin launches Corcal Bone and Beauty supplement

May 10, 2018

Lupin submits New Drug Application for Etanercept biosimilar in Japan

May 08, 2018

Lupin receives FDA approval for generic Temovate Ointment, 0.05%

May 07, 2018

Notice to the Exchanges on Annual Investors Communication

May 03, 2018

Notice to the Exchanges on Annual Investors Meet

May 03, 2018

Notice to the Exchanges on Board Meeting

April 27, 2018

Lupin receives FDA approval for generic Xenazine® Tablets, 12.5 mg and 25 mg

April 23, 2018

Lupin receives tentative FDA approval for generic AndroGel®, 1.62%

April 17, 2018

Lupin’s Softovac in The Economic Times ‘Promising Brands of 2018’

April 09, 2018

Lupin’s Pithampur Unit 1 facility receives Establishment Investigation report (EIR) from US FDA

April 06, 2018

Lupin’s Goa facility completes successful UK MHRA inspection

April 03, 2018

Lupin’s Pithampur Unit cleared by Health Canada

April 02, 2018

Lupin launches generic Clobex® Spray, 0.05% in the US

March 29, 2018

Lupin receives FDA approval for generic Clobex® Spray, 0.05%

March 27, 2018

Lupin launches generic Lodosyn® tablets in the US

March 26, 2018

Lupin receives FDA approval for generic Topicort Topical Spray, 0.25%

March 19, 2018

Lupin launches generic Safyral® tablets in the US

March 13, 2018

Lupin signs an agreement with CSIR-NCL and DST for the development of a continuous manufacturing process for biosimilar monoclonal antibody therapeutic (mAb)

March 08,2018

Lupin launches generic Axiron® topical solution in the US

February 26, 2018

Lupin launches generic Namenda XR® capsules in the US

February 21,2018

Lupin receives FDA approval for generic Tamiflu® for Oral Suspension

February 21, 2018

Lupin receives tentative FDA approval for generic Locoid® Lotion

February 12,2018

Lupin launches generic Tamiflu® in the US

February 12, 2018

Lupin launches generic Kapvay® tablets in the US

February 08,2018

Lupin and Yoshindo's JV – YL Biologics announces successful outcome of global Phase III study for Etanercept biosimilar in Rheumatoid Arthritis

February 07, 2018

Lupin Quarter III, FY2018 - Results

February 06,2018

Lupin launches generic Clobex® Lotion in the US

February 01, 2018

Lupin receives FDA approval for generic Temovate Cream, 0.05%

February 01,2018

Notice to the Exchanges on Board Meeting

January 25, 2018

Lupin launches generic Vibra-Tabs® Tablet in the US

January 19,2018

Lupin forays into the OTC segment with Softovac

January 15, 2018

Lupin receives FDA approval for generic Tamiflu Capsules

January 10,2018

Lupin launches generic Ancobon® capsules in the US

January 05, 2018

Lupin receives FDA approval for generic Temovate Ointment, 0.05%

VIEW ALL PRESS RELEASESS